2019
DOI: 10.1016/j.ccr.2019.07.008
|View full text |Cite
|
Sign up to set email alerts
|

Chemistry and reactivity of ruthenium(II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
80
0
4

Year Published

2019
2019
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 141 publications
(97 citation statements)
references
References 135 publications
2
80
0
4
Order By: Relevance
“…Aquation of the monodentate ligand (X) is a common behaviour for half-sandwich complexes of the type [(arene/Cp)M( N U N )X] and it is usually considered an activation step, which allows further reactions with the corresponding targets [ 39 , 60 , 61 , 62 ]. To study if aquation of complexes 1 – 4 occurs in MeOD/D 2 O (1:1 v / v ), experiments in the presence of either one molar equivalent of silver nitrate (to force the release of the monodentate Cl - ligand), or NaCl (to block hydrolysis), were performed.…”
Section: Resultsmentioning
confidence: 99%
“…Aquation of the monodentate ligand (X) is a common behaviour for half-sandwich complexes of the type [(arene/Cp)M( N U N )X] and it is usually considered an activation step, which allows further reactions with the corresponding targets [ 39 , 60 , 61 , 62 ]. To study if aquation of complexes 1 – 4 occurs in MeOD/D 2 O (1:1 v / v ), experiments in the presence of either one molar equivalent of silver nitrate (to force the release of the monodentate Cl - ligand), or NaCl (to block hydrolysis), were performed.…”
Section: Resultsmentioning
confidence: 99%
“…This proposition was confirmed for one of the most studied ruthenium complexes, the NAMI-A (Figure 1), an efficient anti-metastatic drug. Alessio and co-workers 2 have demonstrated that to be active, in vivo, the NAMI-A acts as prodrugs under physiological conditions. Researchers [15][16][17][18][19] have suggested that the reduction of the Ru III /Ru II is important to produce a more labile complex, which rapidly reacts with specific sites of biomolecules, improving its antitumor activity.…”
Section: Introductionmentioning
confidence: 99%
“…Although cisplatin and second generation platinum-based drugs are efficacious against many types of cancer [1][2][3][4], their use is associated with some restrictions, such as a limited selectivity leading to adverse side-effects and intrinsic or acquired resistance [5][6][7][8][9]. These limitations have fueled the research for the development of anticancer agents based on transition metals other than platinum [10][11][12][13][14][15][16][17][18][19][20][21], and in this respect mono-iron cyclopentadienyl compounds have been investigated, with substituted ferrocenes emerging as highly promising candidates [22][23][24]. Nevertheless, studies on poly-iron organometallic complexes still remain rare [25], and also iron-carbonyl compounds have been scarcely explored in the field so far [26][27][28].…”
Section: Introductionmentioning
confidence: 99%